KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330 | -19.9% | 10,337 | +0.9% | 0.00% | -100.0% |
| Q2 2023 | $412 | -4.2% | 10,245 | +1.8% | 0.00% | 0.0% |
| Q1 2023 | $430 | -31.4% | 10,067 | -22.9% | 0.00% | 0.0% |
| Q4 2022 | $627 | -99.9% | 13,052 | +3.9% | 0.00% | 0.0% |
| Q3 2022 | $472,000 | +55.3% | 12,559 | +14.0% | 0.00% | – |
| Q2 2022 | $304,000 | -49.3% | 11,014 | -0.2% | 0.00% | -100.0% |
| Q1 2022 | $600,000 | -7.0% | 11,037 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $645,000 | +47.6% | 11,027 | -0.3% | 0.00% | – |
| Q3 2021 | $437,000 | -28.0% | 11,058 | -22.7% | 0.00% | -100.0% |
| Q2 2021 | $607,000 | -17.1% | 14,302 | +20.2% | 0.00% | 0.0% |
| Q1 2021 | $732,000 | -6.5% | 11,900 | +7.2% | 0.00% | 0.0% |
| Q4 2020 | $783,000 | +217.0% | 11,100 | +73.4% | 0.00% | – |
| Q3 2020 | $247,000 | +2.9% | 6,400 | 0.0% | 0.00% | – |
| Q2 2020 | $240,000 | – | 6,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |